Skip to main content
Top
Gepubliceerd in: Quality of Life Research 2/2008

01-03-2008

Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy

Auteurs: Se Hoon Park, Moon Sook Cho, Young Saing Kim, Junshik Hong, Eunmi Nam, Jinny Park, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee, Woon Kee Lee

Gepubliceerd in: Quality of Life Research | Uitgave 2/2008

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

To determine whether patients’ self-reported quality-of-life (QOL) parameters could predict survival for patients with advanced gastric cancer (AGC) treated with first-line chemotherapy, we performed this analysis based on the data obtained from 254 patients enrolled in three consecutive prospective randomized trials at a single institution.

Methods

Consenting patients with AGC received first-line chemotherapy as specified in the protocols. QOL was assessed at baseline using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaires. Baseline univariate and multivariate analyses were performed on the QOL data and the recognized clinical predictors for survival.

Results

Of 254 patients, 164 completed the QOL questionnaire at baseline. All patients received fluorouracil-containing first-line chemotherapy for AGC. With 88% observed deaths and a reported median survival of 9.5 months [95% confidence interval (CI) 8.8–10.2 months], there were no significant differences in survival between patients with or without QOL data. The final Cox multivariate model revealed four prognostic factors: age [hazard ratio (HR) 2.08, 95% CI 1.32–3.33, P = 0.002], bone metastasis (HR 2.70, 95% CI 1.30–5.56, P = 0.008), hemoglobin (HR 0.58, 95% CI 0.37–0.92, P = 0.020), and social functioning (HR 0.40, 95% CI 0.23–0.64, P = 0.001). When adjusting for clinical parameters, social functioning was an independently significant prognostic factor for longer survival.

Conclusion

Baseline social functioning, along with age, presence of bone metastasis, and baseline hemoglobin level, independently predicts survival of AGC patients treated with first-line chemotherapy. QOL assessment should be routinely included to provide useful prognostic information concerning AGC patients.
Literatuur
1.
go back to reference Bae, J. M., Won, Y. J., Jung, K. W., & Park, J. G. (2002). Annual report of the Korean Central Cancer Registry Program 2000. Cancer Research and Treatment, 34, 77–83. Bae, J. M., Won, Y. J., Jung, K. W., & Park, J. G. (2002). Annual report of the Korean Central Cancer Registry Program 2000. Cancer Research and Treatment, 34, 77–83.
2.
go back to reference Glimelius, B., Ekstrom, K., Hoffman, K., et al. (1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Annals of Oncology, 8, 163–168.PubMedCrossRef Glimelius, B., Ekstrom, K., Hoffman, K., et al. (1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Annals of Oncology, 8, 163–168.PubMedCrossRef
3.
go back to reference Pyrhonen, S., Kuitunen, T., Nyandoto, P., & Kouri, M. (1995). Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. British Journal of Cancer, 71, 587–591.PubMed Pyrhonen, S., Kuitunen, T., Nyandoto, P., & Kouri, M. (1995). Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. British Journal of Cancer, 71, 587–591.PubMed
4.
go back to reference Bamias, A., & Pavlidis, N. (1998). Systemic chemotherapy in gastric cancer: Where do we stand today? Oncologist, 3, 171–177.PubMed Bamias, A., & Pavlidis, N. (1998). Systemic chemotherapy in gastric cancer: Where do we stand today? Oncologist, 3, 171–177.PubMed
5.
go back to reference Van Cutsem, E. (2004). The treatment of advanced gastric cancer: New findings on the activity of the taxanes. Oncologist, 9 Suppl 2, 9–15. Van Cutsem, E. (2004). The treatment of advanced gastric cancer: New findings on the activity of the taxanes. Oncologist, 9 Suppl 2, 9–15.
6.
go back to reference Chau, I., Norman, A. R., Cunningham, D., et al. (2004). Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer–pooled analysis from three multicenter, randomized, controlled trials using individual patient data. Journal of Clinical Oncology, 22, 2395–2403.PubMedCrossRef Chau, I., Norman, A. R., Cunningham, D., et al. (2004). Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer–pooled analysis from three multicenter, randomized, controlled trials using individual patient data. Journal of Clinical Oncology, 22, 2395–2403.PubMedCrossRef
7.
go back to reference Lee, J., Lim, T., Uhm, J., et al. (2007). Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Annals of Oncology, 18, 886–891.PubMedCrossRef Lee, J., Lim, T., Uhm, J., et al. (2007). Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Annals of Oncology, 18, 886–891.PubMedCrossRef
8.
go back to reference Stephens, R. J., Hopwood, P., & Girling, D. J. (1999). Defining and analysing symptom palliation in cancer clinical trials: A deceptively difficult exercise. British Journal of Cancer, 79, 538–544.PubMedCrossRef Stephens, R. J., Hopwood, P., & Girling, D. J. (1999). Defining and analysing symptom palliation in cancer clinical trials: A deceptively difficult exercise. British Journal of Cancer, 79, 538–544.PubMedCrossRef
9.
go back to reference Dancey, J., Shepherd, F. A., Gralla, R. J., & Kim, Y. S. (2004). Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial. Lung Cancer, 43, 183–194.PubMedCrossRef Dancey, J., Shepherd, F. A., Gralla, R. J., & Kim, Y. S. (2004). Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial. Lung Cancer, 43, 183–194.PubMedCrossRef
10.
go back to reference Maione, P., Perrone, F., Gallo, C., et al. (2005). Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: A prognostic analysis of the multicenter Italian lung cancer in the elderly study. Journal of Clinical Oncology, 23, 6865–6872.PubMedCrossRef Maione, P., Perrone, F., Gallo, C., et al. (2005). Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: A prognostic analysis of the multicenter Italian lung cancer in the elderly study. Journal of Clinical Oncology, 23, 6865–6872.PubMedCrossRef
11.
go back to reference Kramer, J. A., Curran, D., Piccart, M., et al. (2000). Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. European Journal of Cancer, 36, 1498–1506.PubMedCrossRef Kramer, J. A., Curran, D., Piccart, M., et al. (2000). Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. European Journal of Cancer, 36, 1498–1506.PubMedCrossRef
12.
go back to reference Blazeby, J. M., Brookes, S. T., & Alderson, D. (2001). The prognostic value of quality of life scores during treatment for oesophageal cancer. Gut, 49, 227–230.PubMedCrossRef Blazeby, J. M., Brookes, S. T., & Alderson, D. (2001). The prognostic value of quality of life scores during treatment for oesophageal cancer. Gut, 49, 227–230.PubMedCrossRef
13.
go back to reference Dancey, J., Zee, B., Osoba, D., et al. (1997). Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Quality of Life Research, 6, 151–158.PubMedCrossRef Dancey, J., Zee, B., Osoba, D., et al. (1997). Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Quality of Life Research, 6, 151–158.PubMedCrossRef
14.
go back to reference Park, S. H., Nam, E., Bang, S. M., et al. (2008). A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer. Cancer Chemotherapy Pharmacology (in press). doi:10.1007/s00280-007-0561-1. Park, S. H., Nam, E., Bang, S. M., et al. (2008). A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer. Cancer Chemotherapy Pharmacology (in press). doi:10.​1007/​s00280-007-0561-1.
15.
go back to reference Park, S. H., Lee, W. K., Chung, M., et al. (2006). Paclitaxel versus docetaxel for advanced gastric cancer: A randomized phase II trial in combination with infusional 5-fluorouracil. Anticancer Drugs, 17, 225–229.PubMedCrossRef Park, S. H., Lee, W. K., Chung, M., et al. (2006). Paclitaxel versus docetaxel for advanced gastric cancer: A randomized phase II trial in combination with infusional 5-fluorouracil. Anticancer Drugs, 17, 225–229.PubMedCrossRef
16.
go back to reference Park, S. H., Nam, E., Park, J., et al. (2008). Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. Annals of Oncology (in press). doi:10.1093/annonc/mdm502. Park, S. H., Nam, E., Park, J., et al. (2008). Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. Annals of Oncology (in press). doi:10.​1093/​annonc/​mdm502.
17.
go back to reference Aaronson, N. K., Ahmedzai, S., Bergman, B., et al. (1993). The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365–376.PubMedCrossRef Aaronson, N. K., Ahmedzai, S., Bergman, B., et al. (1993). The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365–376.PubMedCrossRef
18.
go back to reference Yun, Y. H., Park, Y. S., Lee, E. S., et al. (2004). Validation of the Korean version of the EORTC QLQ-C30. Quality of Life Research, 13, 863–868.PubMedCrossRef Yun, Y. H., Park, Y. S., Lee, E. S., et al. (2004). Validation of the Korean version of the EORTC QLQ-C30. Quality of Life Research, 13, 863–868.PubMedCrossRef
19.
go back to reference Fayers, P. M., Aaronson, N. K., Bjordal, K., et al. (2001). EORTC QLQ-C30 scoring manual (3rd ed.). Brussels, Belgium: EORTC Quality of Life Group 2001. Fayers, P. M., Aaronson, N. K., Bjordal, K., et al. (2001). EORTC QLQ-C30 scoring manual (3rd ed.). Brussels, Belgium: EORTC Quality of Life Group 2001.
20.
go back to reference Park, S. H., Lee, J., Lee, S. H., et al. (2006). Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 57, 91–96.PubMedCrossRef Park, S. H., Lee, J., Lee, S. H., et al. (2006). Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 57, 91–96.PubMedCrossRef
21.
go back to reference Coates, A., Gebski, V., Signorini, D., et al. (1992). Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. Journal of Clinical Oncology, 10, 1833–1838.PubMed Coates, A., Gebski, V., Signorini, D., et al. (1992). Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. Journal of Clinical Oncology, 10, 1833–1838.PubMed
22.
go back to reference Coates, A., Porzsolt, F., & Osoba, D. (1997). Quality of life in oncology practice: Prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. European Journal of Cancer, 33, 1025–1030.PubMedCrossRef Coates, A., Porzsolt, F., & Osoba, D. (1997). Quality of life in oncology practice: Prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. European Journal of Cancer, 33, 1025–1030.PubMedCrossRef
Metagegevens
Titel
Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy
Auteurs
Se Hoon Park
Moon Sook Cho
Young Saing Kim
Junshik Hong
Eunmi Nam
Jinny Park
Eun Kyung Cho
Dong Bok Shin
Jae Hoon Lee
Woon Kee Lee
Publicatiedatum
01-03-2008
Uitgeverij
Springer Netherlands
Gepubliceerd in
Quality of Life Research / Uitgave 2/2008
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-008-9307-8

Andere artikelen Uitgave 2/2008

Quality of Life Research 2/2008 Naar de uitgave